Literature DB >> 30246613

Improved quality of life following constraint-induced movement therapy is associated with gains in arm use, but not motor improvement.

Kristina M Kelly1, Alexandra L Borstad2, David Kline3, Lynne V Gauthier1.   

Abstract

BACKGROUND: Constraint-induced movement therapy (CI therapy) is one of few treatments for upper extremity (UE) hemiparesis that has been shown to result in motor recovery and improved quality of life in chronic stroke. However, the extent to which treatment-induced improvements in motor function versus daily use of the more affected arm independently contribute to improved quality of life remains largely unexplored.
OBJECTIVE: The objective of this study is to identify whether motor function or daily use of a hemiparetic arm has a greater influence on quality of life after CI therapy.
METHODS: Two cohorts of participants with chronic stroke received either in-person CI therapy (n = 29) or video-game home-based CI therapy (n = 16). The two cohorts were combined and the motor-related outcomes (Wolf Motor Function Test, Action Research Arm Test, Motor Activity Log [MAL]) and quality of life (Stroke-Specific Quality of Life) were jointly modeled to assess the associations between outcomes.
RESULTS: The only outcome associated with improved quality of life was the MAL. Improvements in quality of life were not restricted to motor domains, but generalized to psychosocial domains as well.
CONCLUSIONS: Results suggest that improved arm use during everyday activities is integral to maximizing quality of life gains during motor rehabilitation for chronic post-stroke UE hemiparesis. In contrast, gains in motor function were not associated with increases in quality of life. These findings further support the need to implement techniques into clinical practice that promote arm use during daily life if improving quality of life is a main goal of treatment. ClinicalTrials.gov Registration Numbers: NCT01725919 and NCT03005457.

Entities:  

Keywords:  Constraint-induced movement therapy; behaviour change; chronic stroke; hemiparesis; motor recovery; quality of life; transfer package

Mesh:

Year:  2018        PMID: 30246613      PMCID: PMC6359892          DOI: 10.1080/10749357.2018.1481605

Source DB:  PubMed          Journal:  Top Stroke Rehabil        ISSN: 1074-9357            Impact factor:   2.119


  6 in total

1.  Suitability of accelerometry as an objective measure for upper extremity use in stroke patients.

Authors:  Anne-Lisa Heye; Christine Kersting; Malte Kneer; Anne Barzel
Journal:  BMC Neurol       Date:  2022-06-15       Impact factor: 2.903

2.  Predicting Improved Daily Use of the More Affected Arm Poststroke Following Constraint-Induced Movement Therapy.

Authors:  Mohammad H Rafiei; Kristina M Kelly; Alexandra L Borstad; Hojjat Adeli; Lynne V Gauthier
Journal:  Phys Ther       Date:  2019-12-16

3.  Constraint-induced movement therapy protocols using the number of repetitions of task practice: a systematic review of feasibility and effects.

Authors:  Auwal Abdullahi; Sevim Acaroz Candan; Melda Soysal Tomruk; Abdulsalam Mohammed Yakasai; Steven Truijen; Wim Saeys
Journal:  Neurol Sci       Date:  2021-04-22       Impact factor: 3.307

4.  Self-Directed Exergaming for Stroke Upper Limb Impairment Increases Exercise Dose Compared to Standard Care.

Authors:  Michelle Broderick; Leeza Almedom; Etienne Burdet; Jane Burridge; Paul Bentley
Journal:  Neurorehabil Neural Repair       Date:  2021-08-27       Impact factor: 3.919

5.  Predictors of Clinically Important Improvements in Motor Function and Daily Use of Affected Arm after a Botulinum Toxin A Injection in Patients with Chronic Stroke.

Authors:  Jen-Wen Hung; Wen-Chi Wu; Yi-Ju Chen; Ya-Ping Pong; Ku-Chou Chang
Journal:  Toxins (Basel)       Date:  2021-12-23       Impact factor: 4.546

6.  Relationship Between Body-Specific Attention to a Paretic Limb and Real-World Arm Use in Stroke Patients: A Longitudinal Study.

Authors:  Ryoji Otaki; Yutaka Oouchida; Naoki Aizu; Tamami Sudo; Hiroshi Sasahara; Yuki Saito; Sunao Takemura; Shin-Ichi Izumi
Journal:  Front Syst Neurosci       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.